Milestones Important Moments in the History of BCT 2019 Initiation of a biomarker assay development study for arginine depletion therapy in cancers 2017 A complete remission in a stage IV melanoma patient who had previously been treated by immunotherapies and a complete remission in a prostate cancer patient seen in the US phase I trial in arginine auxotrophic cancers The IMPD submission to UK’s MHRA for BCT’s UK clinical trials in AML accepted 2012 IND approval from US FDA for BCT-100 in arginine-auxotrophic solid tumours 2010 Ministry of Science and Technology of China recognized the BCT-100 project in the “Key New Drug Creation and Manufacturing Program” and one of the key projects within the Eleventh Five-Year Plan; received grants from the PRC Central Government and Shanghai Municipal Government 2005 Received Special Gold Awards at the 33rd International Exhibition of Inventions, New Techniques and Products in Geneva, Switzerland, for the treatment of liver cancer 2001 Initiated feasibility study on using recombinant human arginase 1 in the treatmer malignancies in collaberation with the Hong Kong Polytechnic University
